Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP. episode artwork

EPISODE · Nov 12, 2025 · 12 MIN

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

from BiotechTV - News · host BiotechTV

CEO Michael Henderson walks us through what will be a busy year for the company.

CEO Michael Henderson walks us through what will be a busy year for the company.

NOW PLAYING

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

0:00 12:26

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 12 minutes long.

When was this BiotechTV - News episode published?

This episode was published on November 12, 2025.

What is this episode about?

CEO Michael Henderson walks us through what will be a busy year for the company.

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!